Poly (ADP-ribose) polymerase 1 and Parkinson's disease: A study in post-mortem human brain.


Journal

Neurochemistry international
ISSN: 1872-9754
Titre abrégé: Neurochem Int
Pays: England
ID NLM: 8006959

Informations de publication

Date de publication:
03 2021
Historique:
received: 25 08 2020
revised: 06 01 2021
accepted: 23 01 2021
pubmed: 1 2 2021
medline: 16 11 2021
entrez: 31 1 2021
Statut: ppublish

Résumé

Poly (ADP-ribose) polymerase 1 (PARP1) is crucial in both maintenance of genome integrity and cell death. PARP1 activation has been very recently linked to Parkinson's disease (PD) and its role in inducing the pathologic accumulation of α-Synuclein demonstrated in a PD mouse model. The objective of this study was to investigate the presence and localization of PARP1 in PD brain. PARP1 localization was assessed by immunostaining and confocal microscopy in post-mortem human brains obtained from PD patients (Braak stage VI) compared to controls. PARP1 positive nuclei in substantia nigra, mainly in dopaminergic neurons but also in astrocytes and oligodendrocytes, were decreased in PD. The same alteration was observed in several areas that are affected in PD pathology, namely the dorsal motor nucleus of vagus, frontal and cingulate cortex, whereas no changes in PARP1 staining were detectable in the inferior olivary nucleus that is unaffected in PD. In addition, PARP1 co-localizes with α-Synuclein that is accumulated in the cytoplasm and in Lewy bodies of PD tissue sections. Our data reveal previously unknown changes of PARP1 localization in the brain of PD patients, in both neurons and glia, supporting its widespread involvement in this pathology and its potential use as a therapeutic target.

Identifiants

pubmed: 33516746
pii: S0197-0186(21)00024-3
doi: 10.1016/j.neuint.2021.104978
pii:
doi:

Substances chimiques

alpha-Synuclein 0
PARP1 protein, human EC 2.4.2.30
Poly (ADP-Ribose) Polymerase-1 EC 2.4.2.30

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

104978

Informations de copyright

Copyright © 2021. Published by Elsevier Ltd.

Auteurs

Michele Salemi (M)

Oasi Research Institute-IRCCS, Troina, EN, Italy. Electronic address: micezia@tiscali.it.

Samanta Mazzetti (S)

Fondazione Grigioni per il Morbo di Parkinson, via Zuretti 35, I-20135, Milan, Italy.

Mara De Leonardis (M)

Department of Biosciences, University of Milan, Milan, Italy.

Federica Giampietro (F)

Department of Biosciences, University of Milan, Milan, Italy.

Valentina Medici (V)

Department of Neurology and Neuropathology, Golgi-Cenci Foundation, Abbiategrasso, Milan, Italy.

Tino Emanuele Poloni (TE)

Department of Neurology and Neuropathology, Golgi-Cenci Foundation, Abbiategrasso, Milan, Italy.

Rossella Cannarella (R)

Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.

Giorgio Giaccone (G)

Unit of Neuropathology and Neurology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Gianni Pezzoli (G)

Fondazione Grigioni per il Morbo di Parkinson, via Zuretti 35, I-20135, Milan, Italy.

Graziella Cappelletti (G)

Department of Biosciences, University of Milan, Milan, Italy.

Raffaele Ferri (R)

Oasi Research Institute-IRCCS, Troina, EN, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH